Vertex, Kymera join forces for developing protein degradation drugs
Category: #health  | By Nikita Chaurasia  | Date: 2019-05-17 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Vertex, Kymera join forces for developing protein degradation drugs

Vertex would be paying $70 million in advance to work with Kymera including an equity investment in the company

Kymera Therapeutics and Vertex Pharmaceuticals Incorporated (VRTX) have reportedly announced that they are entering into a four-year research and development partnership to discover and develop small molecule protein degraders against various targets.

Sources close to the matter mentioned that the partnership will leverage Kymera’s expertise in its proprietary Pegasus™ drug discovery platform and in targeted protein degradation and Vertex’s clinical, scientific, and regulatory capabilities. It will boost the development of first in class medicines for people suffering from serious diseases.

According to Senior Vice President and Site Head of Boston Research at Vertex, Mark Bunnage, this partnership with Kymera Therapeutics will improve the company’s drug discovery capabilities and reinforce the approach of investing in scientific innovation to develop transformative drugs for serious diseases.

As per the terms of the four-year deal, Vertex would be paying $70 million in advance to work with Kymera including an equity investment in the company. Under the collaboration, Kymera will conduct research activities in several targets. Once a clinical development candidate is selected, Vertex has the option to completely license molecules against the selected target.

On the other hand, Kymera is also eligible to receive over $1 billion in potential payments based upon the successfully achieving research, development, commercial, and regulatory milestones for up to six programs optioned as part of the partnership, sourced mentioned.

President and CEO of Kymera Therapeutics, Dr. Laurent Audoly, Ph.D., said that this strategic partnership will widen the application of targeted protein degradation for addressing serious diseases having limited or no treatment options.

For the uninitiated, Kymera Therapeutics is a biotechnology company pioneering a new and transformative approach towards treating serious diseases which were previously untreatable. The company advances in the field of targeted protein degradation and disease-causing proteins to tackle substantial unmet medical need.

 

Source Credit: https://finance.yahoo.com/news/vertex-kymera-therapeutics-establish-strategic-123000590.html

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

Samsung kickstarts chip production with 3nm process technology

Samsung kickstarts chip production with 3nm process technology

By Nikita Chaurasia

Samsung Electronics Co Ltd has reportedly declared that it has begun the mass production of chips using advanced 3-nanometre technology. The company is the first in the entire world to do so and is actively looking for new clients to contest with Tai...

Progcap nabs $40Mn in funding round for expansion & product development

Progcap nabs $40Mn in funding round for expansion & product development

By Nikita Chaurasia

Progcap, a pioneer in the field of corporate-driven financing solutions for small and medium-sized businesses (SMBs), has secured $40 million in private equity capital at $600 million valuation. The raised capital forms a part of the Series C exte...

Microsoft solidifies Qatar investment; Unveils new high-tech office

Microsoft solidifies Qatar investment; Unveils new high-tech office

By Nikita Chaurasia

Microsoft, the global tech behemoth, has recently stated that it is expanding its operation in Qatar by unveiling a new Lusail City unit, the firm’s largest and fourth in the country. This new facility forms part of a substantial investment tha...